PAVmed Inc. [NASDAQ: PAVM] traded at a high on 03/17/21, posting a 0.93 gain after which it closed the day’ session at $4.32. The company report on March 10, 2021 that PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference.
On-demand corporate presentation scheduled for March 17, 2021.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer will present a corporate update at the Inaugural Emerging Growth Virtual Conference, held by M Vest LLC and Maxim Group LLC. The conference will take place on March 17th – 19th from 9:00 AM to 5:00 PM EDT.
The results of the trading session contributed to over 5882805 shares changing hands. Over the past one week, the price volatility of PAVmed Inc. stands at 9.96% while the volatility over the past one month is 14.28%.
The market cap for PAVM stock reached $343.09 million, with 48.38 million shares outstanding and 45.77 million shares in the current float. Compared to the average trading volume of 4.30M shares, PAVM reached a trading volume of 5882805 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about PAVmed Inc. [PAVM]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PAVM shares is $7.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PAVM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ascendiant Capital Markets have made an estimate for PAVmed Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 05, 2020. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on June 28, 2018, representing the official price target for PAVmed Inc. stock.
The Average True Range (ATR) for PAVmed Inc. is set at 0.55
How has PAVM stock performed recently?
PAVmed Inc. [PAVM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.09. With this latest performance, PAVM shares dropped by -3.79% in over the last four-week period, additionally plugging by 129.79% over the last 6 months – not to mention a rise of 184.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PAVM stock in for the last two-week period is set at 58.39, with the RSI for the last a single of trading hit 58.23, and the three-weeks RSI is set at 58.99 for PAVmed Inc. [PAVM]. The present Moving Average for the last 50 days of trading for this stock 3.17, while it was recorded at 4.31 for the last single week of trading, and 2.27 for the last 200 days.
PAVmed Inc. [PAVM]: Deeper insight into the fundamentals
PAVmed Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.40 and a Current Ratio set at 0.40.
Earnings analysis for PAVmed Inc. [PAVM]
With the latest financial reports released by the company, PAVmed Inc. posted -0.33/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -200.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PAVM.
Insider trade positions for PAVmed Inc. [PAVM]
There are presently around $39 million, or 11.00% of PAVM stock, in the hands of institutional investors. The top three institutional holders of PAVM stocks are: VANGUARD GROUP INC with ownership of 2,283,826, which is approximately 39.065% of the company’s market cap and around 2.40% of the total institutional ownership; BLACKROCK INC., holding 1,848,227 shares of the stock with an approximate value of $7.98 million in PAVM stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $2.35 million in PAVM stock with ownership of nearly 38.646% of the company’s market capitalization.
Positions in PAVmed Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 36 institutional holders increased their position in PAVmed Inc. [NASDAQ:PAVM] by around 2,345,732 shares. Additionally, 21 investors decreased positions by around 330,714 shares, while 18 investors held positions by with 6,251,527 shares. The mentioned changes placed institutional holdings at 8,927,973 shares, according to the latest SEC report filing. PAVM stock had 14 new institutional investments in for a total of 676,585 shares, while 10 institutional investors sold positions of 111,766 shares during the same period.